Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry

Fatime Hawchar, Dana Tomescu, Karl Träger, Dominik Joskowiak, Klaus Kogelmann, Jens Soukup, Singrun Friesecke, David Jacob, Jan Gummert, Andreas Faltlhauser, Filippo Aucella, Martijn van Tellingen, Manu L N G Malbrain, Ralph Bogdanski, Günter Weiss, Andreas Herbrich, Stefan Utzolino, Axel Nierhaus, Andreas Baumann, Andreas Hartjes, Dietrich Henzler, Evgeny Grigoryev, Harald Fritz, Friedhelm Bach, Stefan Schröder, Andreas Weyland, Udo Gottschaldt, Matthias Menzel, Olivier Zachariae, Radovan Novak, Jernej Berden, Hendrik Haake, Michael Quintel, Stephan Kloesel, Andreas Kortgen, Stephanie Stecher, Patricia Torti, Frieder Nestler, Markus Nitsch, Detlef Olboeter, Philip Muck, Michael Findeisen, Diane Bitzinger, Jens Kraßler, Martin Benad, Martin Schott, Ulrike Schumacher, Zsolt Molnar, Frank Martin Brunkhorst, Fatime Hawchar, Dana Tomescu, Karl Träger, Dominik Joskowiak, Klaus Kogelmann, Jens Soukup, Singrun Friesecke, David Jacob, Jan Gummert, Andreas Faltlhauser, Filippo Aucella, Martijn van Tellingen, Manu L N G Malbrain, Ralph Bogdanski, Günter Weiss, Andreas Herbrich, Stefan Utzolino, Axel Nierhaus, Andreas Baumann, Andreas Hartjes, Dietrich Henzler, Evgeny Grigoryev, Harald Fritz, Friedhelm Bach, Stefan Schröder, Andreas Weyland, Udo Gottschaldt, Matthias Menzel, Olivier Zachariae, Radovan Novak, Jernej Berden, Hendrik Haake, Michael Quintel, Stephan Kloesel, Andreas Kortgen, Stephanie Stecher, Patricia Torti, Frieder Nestler, Markus Nitsch, Detlef Olboeter, Philip Muck, Michael Findeisen, Diane Bitzinger, Jens Kraßler, Martin Benad, Martin Schott, Ulrike Schumacher, Zsolt Molnar, Frank Martin Brunkhorst

Abstract

The aim of the current paper is to summarize the results of the International CytoSorb Registry. Data were collected on patients of the intensive care unit. The primary endpoint was actual in-hospital mortality compared to the mortality predicted by APACHE II score. The main secondary endpoints were SOFA scores, inflammatory biomarkers and overall evaluation of the general condition. 1434 patients were enrolled. Indications for hemoadsorption were sepsis/septic shock (N = 936); cardiac surgery perioperatively (N = 172); cardiac surgery postoperatively (N = 67) and "other" reasons (N = 259). APACHE-II-predicted mortality was 62.0±24.8%, whereas observed hospital mortality was 50.1%. Overall SOFA scores did not change but cardiovascular and pulmonary SOFA scores decreased by 0.4 [-0.5;-0.3] and -0.2 [-0.3;-0.2] points, respectively. Serum procalcitonin and C-reactive protein levels showed significant reduction: -15.4 [-19.6;-11.17] ng/mL; -17,52 [-70;44] mg/L, respectively. In the septic cohort PCT and IL-6 also showed significant reduction: -18.2 [-23.6;-12.8] ng/mL; -2.6 [-3.0;-2.2] pg/mL, respectively. Evaluation of the overall effect: minimal improvement (22%), much improvement (22%) and very much improvement (10%), no change observed (30%) and deterioration (4%). There was no significant difference in the primary outcome of mortality, but there were improvements in cardiovascular and pulmonary SOFA scores and a reduction in PCT, CRP and IL-6 levels. Trial registration: ClinicalTrials.gov Identifier: NCT02312024 (retrospectively registered).

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: KT has received honoraria for lectures and consultations from CytoSorbents Europe (Berlin, Germany); KK has received honoraria for lectures and consultations from CytoSorbents Europe (Berlin, Germany); AF has received honoraria for lectures and consultations from CytoSorbents Europe (Berlin, Germany); FMB has received honoraria for lectures and consultations from CytoSorbents Europe (Berlin, Germany); ZM has received honoraria for lectures and consultations and he also functions as medical director at CytoSorbents Europe (Berlin, Germany). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1. The number of patients by…
Fig 1. The number of patients by indication.
CBP, cardio-pulmonary bypass, OR operating room.
Fig 2. Actual and predicted mortality in…
Fig 2. Actual and predicted mortality in the whole sample.
ITT, number of patients. See text for explanation.
Fig 3. Actual and predicted mortality in…
Fig 3. Actual and predicted mortality in the sepsis cohort.
ITT, number of patients. See text for explanation.

References

    1. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al.. Circulating Mitochondrial DAMPs Cause Inflammatory Responses to Injury. Nature. 2010;464: 104–107. doi: 10.1038/nature08780
    1. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13: 862–874. doi: 10.1038/nri3552
    1. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinksy MR, et al.. Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167: 1655–1663. doi: 10.1001/archinte.167.15.1655
    1. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-cortes A, Brunner MD, et al.. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med. 2006;355: 1018–1028. doi: 10.1056/NEJMoa063842
    1. Zhou F, Peng Z, Murugan R, Kellum JA. Blood Purification and Mortality in Sepsis: A Meta-analysis of Randomized Trials. Crit Care Med. 2014;41: 2209–2220. doi: 10.1097/CCM.0b013e31828cf412.Blood
    1. Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36: 268–272. doi: 10.1097/
    1. Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain MLNG, et al.. Cytokine removal in human septic shock: Where are we and where are we going? Ann Intensive Care. 2019;9. doi: 10.1186/s13613-019-0530-y
    1. Peng Z, Simon P, Rimmelé T, Clermont G, Kellum JA. Blood Purification in Sepsis: A New Paradigm. Contrib Nephrol. 2010. doi: 10.1159/000313773
    1. Esteban E, Ferrer R, Alsina L, Artigas A. Immunomodulation in Sepsis: The Role of Endotoxin Removal by Polymyxin B-Immobilized Cartridge. Mediators Inflamm. 2013;2013. doi: 10.1155/2013/507539
    1. Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019;49: 172–178. doi: 10.1016/j.jcrc.2018.11.003
    1. Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al.. International registry on the use of the CytoSorb® adsorber in ICU patients: Study protocol and preliminary results. Medizinische Klin—Intensivmed und Notfallmedizin. 2017;2017. doi: 10.1007/s00063-017-0342-5
    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al.. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101: 1644–1655. doi: 10.1378/chest.101.6.1644
    1. Outcome DEcIDE Center. Registries for Evaluating Patient Outcomes: A User’s Guide 2nd ed. 2nd ed. Gliklich RE, Dreyer NA, editors. Rockville: Agency for Healthcare Research and Quality; 2010.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13: 818–828. doi: 10.1097/00003465-198603000-00013
    1. Le Gall J-R, Lemeshow S, Saulnier F. Simplified Acute Physiology Score (SAPS II) Based on a European / North American Multicenter Study. J Am Med Assoc. 1993;270: 2957–2963. doi: 10.1001/jama.1993.03510240069035
    1. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al.. EuroSCORE II. Eur J Cardio-Thoracic Surg. 2012;41: 734–745. doi: 10.1093/ejcts/ezs043
    1. Stigler SM. Regression towards the mean, historically considered. Stat Methods Med Res. 1997;6: 103–114. doi: 10.1177/096228029700600202
    1. Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. 2017;20: 252–259. doi: 10.1007/s10047-017-0967-4
    1. Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: A case series. Crit Care. 2017;21: 1–10. doi: 10.1186/s13054-017-1662-9
    1. Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28- day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23: 1–9.
    1. Ho KM, Dobb GJ, Knuiman M, Finn J, Lee KY, Webb SAR. A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study. Crit Care. 2006;10: 1–8. doi: 10.1186/cc3913
    1. Träger K, Skrabal C, Fischer G, Datzmann T, Schroeder J, Fritzler D, et al.. Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass—a case series. Int J Artif Organs. 2017;40: 240–249. doi: 10.5301/ijao.5000583
    1. Kühne L, Binczyk R, Rieß F. Comparison of intraoperative versus intraoperative plus postoperative hemoadsorption therapy in cardiac surgery patients with endocarditis. Int J Artif Organs. 2019;42. doi: 10.1177/0391398818806158
    1. Mitzner SR, Gloger M, Henschel J, Koball S. Improvement of Hemodynamic and Inflammatory Parameters by Combined Hemoadsorption and Hemodiafiltration in Septic Shock: A Case Report. Blood Purif. 2013;35: 314–315. doi: 10.1159/000351206
    1. Tomescu D, Popescu M, David C, Sima R, Dima S. Haemoadsorption by CytoSorb® in patients with acute liver failure: A case series. Int J Artif Organs. 2020. doi: 10.1177/0391398820981383
    1. Kogelmann K, Scheller M, Dru M, Jarczak D. Use of hemoadsorption in severe ARDS: A case series. J Intensive Care Soc. 2018;0: 1–8. doi: 10.1177/1751143718818992
    1. Zuccari S, Damiani E, Domizi R, Scorcella C, D’Arezzo M, Carsetti A, et al.. Changes in Cytokines, Haemodynamics and Microcirculation in Patients with Sepsis/Septic Shock Undergoing Continuous Renal Replacement Therapy and Blood Purification with CytoSorb. Blood Purif. 2020;49: 4–10. doi: 10.1159/000502540
    1. Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al.. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One. 2017;12: 1–19. doi: 10.1371/journal.pone.0187015
    1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.. The third international consensus definitions for sepsis and septic shock. Jama. 2016;315: 801–810. doi: 10.1001/jama.2016.0287.The
    1. Vincent J, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23: 1–11.
    1. Lau K, Shah H, Kelleher A, Moat N. Coronary artery surgery: cardiotomy suction or cell salvage? J Cardiothorac Surg. 2007;2: 1–5. doi: 10.1186/1749-8090-2-46
    1. Apostolakis E, Filos KS, Koletsis E, Dougenis D. Lung Dysfunction Following Cardiopulmonary Bypass. J Card Surg. 2010;25: 47–55. doi: 10.1111/j.1540-8191.2009.00823.x
    1. Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, et al.. Effect of hemoadsorption during cardiopulmonary bypass surgery–a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016;20: 1–13. doi: 10.1186/s13054-016-1270-0
    1. Garau I, März A, Sehner S, Reuter DA, Reichenspurner H, Zöllner C, et al.. Hemadsorption during cardiopulmonary bypass reduces interleukin 8 and tumor necrosis factor α serum levels in cardiac surgery: a randomized controlled trial. Minerva Anestesiol. 2019;85: 715–723. doi: 10.23736/S0375-9393.18.12898-7
    1. Poli EC, Alberio L, Bauer-doerries A, Marcucci C, Roumy A, Kirsch M, et al.. Cytokine clearance with CytoSorb ® during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019;23: 1–12. doi: 10.1186/s13054-019-2399-4
    1. Saller T, Hagl C, Woitsch S, Li Y, Niedermayer S, Born F, et al.. Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest. Eur J Cardio-Thoracic Surg. 2019;56: 731–737. doi: 10.1093/ejcts/ezz074
    1. Nemeth E, Kovacs E, Racz K, Soltesz A, Szigeti S, Kiss N, et al.. Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation–an observational study. Clin Transplant. 2018. doi: 10.1111/ctr.13211
    1. Büttner S, Patyna S, Koch B, Finkelmeier F, Geiger H, Sarrazin C, et al.. Application of Hemoadsorption in a Case of Liver Cirrhosis and Alcohol-Related Steatohepatitis. Blood Purif. 2017;44: 30–31. doi: 10.1159/000455064
    1. Tomescu D, Popescu M, David C, Dima S. Clinical effects of hemoadsorption with CytoSorb ® in patients with severe acute pancreatitis: A case series. Int J Artif Organs. 2019;42: 10–13. doi: 10.1177/0391398818823762
    1. Wiegele M, Krenn CG. Cytosorb TM in a Patient with Legionella Pneumonia–Associated Rhabdomyolysis: A Case Report. Am Soc Artif Intern Organs. 2015; 18–20. doi: 10.1097/MAT.0000000000000197
    1. Giuntoli L, Dalmastri V, Cilloni N, Orsi C, Stalteri L, Demelas V, et al.. Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent. Int J Artif Organs. 2019;42: 1–5. doi: 10.1177/0391398819837686
    1. Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding. Ann Thorac Surg. 2019;108: 45–51. doi: 10.1016/j.athoracsur.2018.12.032
    1. Frimmel S, Hinz M, Schipper J, Bogdanow S, Mitzner S, Koball S. Cytokine adsorption is a promising tool in the therapy of hemophagocytic lymphohistiocytosis. Int J Artif Organs. 2019;42: 1–7. doi: 10.1177/0391398819857444

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅